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Researcher Diane Williams, a gradnate student in 
microbiology, at work in the Biomolecular 
Medicine Section's new laboratory. 
Biomolecular lab 
opening coincides 
with IL'2'toxln trials 
The Biomolecular Medicine Seetion's spacious 
new lahoratory i n the Evans Bui lding em-
hodies the Section's c o m m i t m e n t to fostering 
interdiscipl inary research and patient care 
among Evans departments. A t the 
laboratory's opening ceremony, i t was an-
nounced that the Food and D r u g Adminis t ra -
t i o n had granted approval for Section Chief 
John R. M u r p h y , Ph.D., and his research group 
to conduct c l inical trials of the chimeric IL-2-
tox in , a new class of drugs that attack specific 
leukemias and lymphomas, inc luding adult T-
cell leukemia. 
Dr . Murphy 's w o r k is a pr ime example of 
the interdepartmental ac t iv i ty that the new 
lahoratory was designed to facil itate. The re-
search group, w h i c h includes Ronald 
McCaffrey, M . D . , chief of medical oncology at 
U H , was the first i n scientific l i terature to 
describe the abi l i ty to make these chimeric 
molecules. 
Continued on page 3 
The new 
Biomolecular 
Medicine Laboratory: 
The physical expression 
of a concept developed 
nearly five years ago 
By Norman G . Levinsky, M . D . 
Director, 
Evans Department of Medicine 
Members of the Evans Department have 
always benefited f r o m close w o r k i n g relation-
ships w i t h colleagues i n the basic-science 
departments throughout the Medical Center. 
Nevertheless, the Evans Department of 
Medicine's strategic planning commit tee felt 
that there w o u l d he a special advantage to es-
tablishing a medicine-hased molecular b io l -
ogy program, hecause molecular and cellular 
biology have become a c o m m o n language i n 
most areas of internal medicine. 
Our commit tee recommended that the 
Evans establish a mechanism for integrating 
molecular biologists i n t o the framework of 
our c l inical Department of Medicine i n order 
to enhance collaborative research and the 
tra ining of c l in ica l investigators. As director 
of the Evans, I was enthusiastic about this 
concept. 
Four years ago, we established the Section 
of Biomolecular Medicine and recruited John 
R. M u r p h y , Ph.D., as the f irst scientist i n this 
program. His research focused on a hasic 
problem i n microbiology—the pathohiology 
of diphtheria t o x i n — h u t w i t h a v iew to the 
possible c l in ica l u t i l i t y of the t o x i n i n the 
treatment of h u m a n disease. 
The idea of the presence of hasic scientists 
leading to enhanced research collaborations 
and improved tra ining of c l in ica l inves-
tigators has worked as w e l l i n reality as i t did 
i n theory. Numerous collaborative relation-
ships soon were established between Section 
members and their colleagues i n the Depart-
ment , and any number of faculty and c l in ica l 
trainees have learned both concepts and tech-
Cont inued on page 2 
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The new 
laboratory 
embodies 
the Evans 
Department's 
commitment to 
interdisciplinary 
research and 
patient care. 
The 
University 
Hospital 
A view of a portion of the Section's laboratory space. The laboratory is divided into eight-person suites, 
rather than the usual two- or four-person suites, in order to accommodate expanding research groups. Each 
researcher has his or her own wet-bench area, and common facilities and equipment are located in a central 
area of the floor. A section of the laboratory is designated for use as teaching space hy Evans Department of 
Medicine members and visiting scientists. 
New laboratory 
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niques i n Dr . Murphy ' s lahoratory. T w o 
pr inc ipal investigators also joined the Sec-
t i o n : James Burton, Ph.D., a peptide chemist 
w h o uses molecular model ing to develop i n -
hibi tors of such proteases as renin and k a l l i k -
rein; and Gerhard Heinr ich , M . D . , w h o is 
s tudying the molecular biology of nerve-
g r o w t h factor. 
U n t i l recently, our abi l i ty to recruit more 
scientists to the Section has been l i m i t e d hy 
the available space. W i t h the opening of the 
magnificent new molecular biology fac i l i ty 
on the s ix th f loor of the Evans Building, this 
harrier has been overcome. As luck w o u l d 
have i t , simultaneous w i t h the opening of the 
lahoratory we were ahle to announce the par-
t i c ipat ion of our Medical Oncology Section i n 
the f irst c l inical t r i a l of Dr . Murphy ' s geneti-
cally modif ied diphtheria t o x i n for therapy of 
h u m a n disease (T-cell leukemia and l y m -
phoma.) 
The concept of translating hasic science 
through c l in ica l science for use i n patient 
care is embodied i n the location of the u n i t . 
The new fac i l i ty , appropriately enough, is 
housed between the laboratories of c l inical i n -
vestigators on the five floors below i t and the 
patient-care uni ts located on the seventh and 
eighth floors. 
The open style of the molecular biology 
lahoratory also symbolizes the concept of i n -
teraction among colleagues. The laboratories, 
w h i c h have no internal walls , open onto com-
m o n equipment facilities, designed to 
facil itate the interact ion of the investigators 
w h o are housed on the floor. One area of the 
floor has been designated specifically as a 
t ra ining lahoratory for c l inical fellows and 
faculty. 
M a n y of us w h o have been c l inical inves-
tigators for some t ime have become increas-
ingly concerned hy the fragmentation of c l i n i -
cal research i n t o compartmentalized dis-
ciplines. Perhaps this is an explanation for 
the declining attendance at the spring C l i n i -
cal Investigation meeting, once the universal-
l y acknowledged meeting place for c l inician-
investigators, w h i c h now is becoming secon-
dary to the many subspecialty meetings held 
each year. 
Despite this fragmentation, the language 
of research is, i n fact, becoming more com-
prehensible to scientists i n al l subspecialties 
of medicine, as molecular and cellular biology 
are becoming a common language for al l 
scientists. I believe that this is a positive 
development for c l inical science. I am grate-
f u l to the Trustees of the Evans, w h o have 
made i t possible for us to b u i l d on our i n i t i a l 
success i n developing an integrating core i n 
molecular biology hy providing resources for 
our new lahoratory. • 
Despite the 
fragmentation of 
cilnicai research, 
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Clinical trial Initiated 
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Dr. M u r p h y is the principal investigator of 
the project, w h i c h involved the genetic l i n k -
ing of inter leukin-2 (IL-2), a protein g r o w t h 
factor needed hy some leukemia cells, w i t h a 
por t ion of the diphtheria t o x i n molecule. IL-
2-toxin, the new molecule, is ahsorhed hy the 
leukemia and l y m p h o m a cells as if i t were 
pure IL-2. Once inside the cell, the diphtheria 
t o x i n component is ahle to attack and destroy 
that cell . 
Pioneering research efforts 
"We are pioneering research and c l in ica l ef-
forts i n this area, and we've been able to 
make such progress hecause of close collabora-
tions i n the medical c o m m u n i t y , " notes Dr . 
M u r p h y . Last fa l l , he was awarded a five-
year, $2 .3 -mi l l ion cooperative agreement 
f r o m the N a t i o n a l Cancer Inst i tute to con-
t inue his w o r k . 
The awarding of the agreement to U H , 
w h i c h is one of only nine NCI-supported Na-
t ional Cooperative D r u g Discovery Croups i n 
the U.S., "recognizes the successful merging 
of hasic and c l inical research at the Hospital , " 
according to Dr . M u r p h y . 
The Insti tute 's innovat ive N a t i o n a l 
Cooperative D r u g Discovery Croup program 
encourages interact ion among academic and 
commercial interests i n partnership w i t h N C I 
to discover new strategies for the treatment 
of cancer. The Univers i ty Hospital Discovery 
Croup includes researchers f r o m Beth Israel 
Hospita l and Brigham and Women's Hospital 
i n Boston, the Nat iona l Cancer Inst i tute and 
Seragen, Inc., a biotechnology f i r m based i n 
H o p k i n t o n , Mass. 
Dr. McCaffrey is a t tempt ing to ident i fy 
both the types of leukemias and lymphomas 
that have the receptor needed to b ind the new 
tox in , and the conditions under w h i c h these 
leukemias and lymphomas can he k i l l e d hy 
the t o x i n . This spring, c l in ica l trials of the 
drug w i l l be conducted at U H under Dr . 
McCaffrey's direction,- c l in ica l trials already 
are under way at M . D . Anderson Hospital i n 
Texas. 
"This award allows us to approach the 
treatment of leukemia and lymphoma i n a 
whole new way," Dr . McCaffrey explained 
when the award was announced last fa l l . " In 
the future, the technology w i l l be adapted to 
almost any f o r m of cancer, such as lung can-
cer and melanoma, that is dependent on a 
g r o w t h factor." 
New level of excitement 
Dr. M u r p h y explains that the development 
of IL-2- toxin is a pr ime example of what he 
refers to as "tweener" research—research that 
straddles the hasic sciences and the c l in ica l 
sciences, w i t h the a i m of bringing the t w o 
areas together "so that the powerful technol-
ogy we have at our disposal can he used for 
better understanding disease states that can-
not he well-managed therapeutically." 
Scientists interested i n conducting 
"tweener" research activit ies are being active-
Dr. Murphy, left, at the reception for the new laboratory with Drs. 
McCaffrey, Levinsky, and J. Scott Abercrombie Jr., M . D . , president of the 
University Hospital. 
l y recruited hy the Section, w h i c h now has ap-
proximately 20 investigators on staff. " U l -
t imate ly , we w o u l d l ike to have 50 people 
w o r k i n g here, inc luding five or six pr incipal 
investigators," Dr . M u r p h y says. Current ly , 
Dr . M u r p h y , James Burton, Ph.D., and Ger-
hard Heinr ich , M . D . , are the Section's p r i n -
cipal investigators. 
"What we w o u l d l ike to convey to prospec-
t ive staff members is the level of excitement 
i n the Section regarding not only the physical 
space, but i n providing an environment only 
one f l ight of stairs away f r o m patients, staffed 
by hasic and c l in ica l scientists w h o are bring-
ing the power of molecular biology to the 
treatment of h u m a n disease," says Dr . 
M u r p h y . 
" I look at the 1990s as the era of biologi-
cals, hecause i t offers us the capability of 
m o d i f y i n g biological responses i n a very selec-
tive way. This is an extraordinarily excit ing 
era i n medical research." 
Dr . M u r p h y cites IL-2- toxin as an example 
of the Section's w o r k i n genetic orchestra-
t i o n . "It's a new molecule designed deliberate-
l y to carry out its functions, constructed 
genetically using protein engineering and 
recombinant D N A methodology, and now i n -
troduced into c l inical trials. This is an agent 
that never has been seen before: It 's not l ike 
penic i l l in , w h i c h is something that occurs 
natural ly and was discovered hy accident." 
Fostering common understanding 
"For the f irst t ime , we can design new 
biologicals and put together molecules f r o m 
disparate components to f o r m new 
molecules," he adds. "To have the privilege of 
doing this w o r k i n a c o m m u n i t y such as the 
Evans, where there is m u t u a l respect, under-
standing and c o m m o n goals among the staff, 
is very satisfying." 
The new biomolecular medicine 
lahoratory is designed to foster the k i n d of i n -
terdisciplinary ac t iv i ty that went i n t o 
developing IL-2- toxin . That w o r k represents 
Murphy 's hopes for future collegial projects 
between other Section investigators and their 
colleagues throughout the Department. "We 
wanted a f loor that w o u l d maximize the op-
Cont inued on page 4 
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the new research 
unit are working to 
bring the power 
of molecular 
biology to the 
treatment of 
human disease.' 
Lee Fong Jean, a graduate student in microbiology, 
programs the computer for the synthesis of a D N A 
fragment. 
Clinical trial initiated 
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portunities for interaction among everyone 
from principal investigators to technicians and 
postdoctoral students," Dr. Murphy explains. 
"Because the Section's unique mandate is 
somewhat hke that of a working library, our 
mission is to provide a center of excellence for 
molecular biology and genetics, where others 
in the Evans Department of Medicine can 
learn these methodologies and apply that 
knowledge to their own research," he explains. 
"The methodologies used in different re-
search projects essentially are the same, and 
the design of the new laboratory makes it 
easier for all of us to benefit from one 
another's experience in using these techni-
ques." 
Unique design approach 
The layout of the 18,000-square-foot 
fac i l i ty (from exterior w a l l to exterior w a l l , i n -
c luding shafts) is unique for the Evans; i n fact, 
i t is an unusual design for a research fac i l i ty 
anywhere. "Most sophisticated biomolecular 
laboratories of this k i n d are found only i n 
basic-science departments or i n research i n -
st i tut ions where hasic research scientists have 
l i t t l e or no contact w i t h patients or 
physicians," according to Dr . Levinsky. 
The project manager for the construction 
was Cur t Heuring, an architect w i t h 
Ellenzweig Associates, Inc., i n Cambridge. 
Heur ing credits Drs. M u r p h y and Levinsky 
w i t h being open to a l lowing his f i r m to ex-
plore this rather untradi t ional design. 
"Typical ly , research laboratories are 
recessed off a corridor i n dist inct , separate 
spaces," Heur ing comments. "Dr. M u r p h y and 
Dr . Levinsky were w i l l i n g to consider the 
possihi l i ty of opening up the lah and removing 
any barriers—hallways, walls , doors. The 
result is an open, combined lahoratory-office-
research fac i l i ty . 
" In m y experience, there is a tendency 
among researchers to say 'This is m y space, 
equipment and experiment. ' A l t h o u g h many 
talk about the idea of an open lahoratory, very 
few w i l l make a c o m m i t m e n t to i t . I t took a 
great leap of fa i th on the part of the people at 
U H to go through w i t h this." 
"We felt very strongly that the lahoratory 
should he designed i n as open a configuration 
as possible, w i t h each lah identical to the 
others," notes Dr . M u r p h y . "We wanted to 
maximize the amount of bench space and 
m i n i m i z e the space not used i n the execution 
of research." 
One of the floor's unique design features is 
the divis ion of the laboratory space in to eight-
person lah suites, rather than the customary 
t w o - or four-person suites. This configuration 
was used i n order to accommodate expanding 
research groups and, hopefully, grants. Each 
researcher has his or her o w n wet-hench area, 
w h i l e common facilities and equipment, such 
as the ultracentrifuge, are located i n a central 
area. 
"Undertaking research is so expensive that 
we felt i t w o u l d he advantageous to pool our 
f inancial resources i n order to purchase equip-
ment for the Section," Dr . M u r p h y continues. 
"Eor many research activities, equipment may 
only be needed short-term; if researchers al-
ready have access to equipment, l ike a D N A 
synthesizer, t h e y ' l l he that m u c h more l i k e l y 
to receive funding for their w o r k , hecause 
they can do experiments that require special 
ins t rumentat ion w i t h o u t having to request 
funds to purchase equipment." 
The Section also has dedicated a sig-
ni f icant por t ion of the new lahoratory to 
teaching space, w h i c h is used hy members of 
other sections w i t h i n the Evans Department 
of Medicine as w e l l as hy v is i t ing groups who 
w o u l d l ike to take advantage of the expertise 
of Section members to further their research. 
"We encourage v is i t ing scientists and 
others w h o use this fac i l i ty to ask for our help 
i n conducting their research. This is an open, 
interactive environment, and part of our mis-
sion is to provide the training, equipment and 
advice necessary to further the research ac-
t iv i t ies of our Medical Center colleagues and 
others w h o use our facilities," says M u r p h y . • 
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Mycologists In the Evans explore the 
complexities of systemic fungal Infections 
The growing suhspeeialty of medical mycol -
ogy is w e l l represented w i t h i n the Evans Infec-
tious Disease Section, where the pr imary, al-
though hy no means exclusive, research inter-
est is systemic fungal infections. 
A number of ongoing research projects con-
ducted by Section medical mycologists and 
their colleagues may hold promise for those 
immunocompromised populations w h o are 
part icular ly at r isk of developing fungal infec-
t ions: patients w i t h acquired i m m u n e 
deficiency syndrome (AIDS), organ-transplant 
recipients, people w i t h certain types of 
tumors, patients w i t h leukemia and, possibly, 
steroid-users. 
"Eungal infections used to he medical 
curiosities, but i t 's clear that the occurrence 
of these infections, and the recognition of 
their importance, has been increasing since 
the 1950s," explains Richard D . Diamond, 
M . D . , chief of the Section. 
Dr . D i a m o n d attributes this rise to the i n -
creasing immunosuppression of the popula-
t i o n : cortisone was discovered i n the 1950s; 
chemotherapy hecame popular, controlled and 
useful; organ transplantation was started i n 
that era and advanced very rapidly, particular-
l y i n the 1960s. 
"Because medicine has advanced so far that 
we can keep people alive i n a compromised 
i m m u n e state, fungal illnesses have become 
problems of increasing magnitude," Dr . 
D i a m o n d notes. " A t the same t ime, we are 
better ski l led i n diagnosing and treating bac-
terial illnesses, w h i c h are s t i l l the major r isk 
to immunocompromised patients." 
A rare depth of expertise 
A l a n M . Sugar, M . D . , one of the Section's 
four mycologists (more than any other hospi-
ta l i n N e w England), notes that i t is unusual 
for a hospital to have so many researchers 
studying fungal infections, part icularly the 
more "exotic" varieties of disease that often 
are not w e l l understood hy physicians. "The 
combined interest of the staff focuses on 
pathogenesis, basic lahoratory and treatment 
issues," he explains. "Our depth of expertise 
al lows us to offer patients more than the tradi-
t iona l drug therapies." 
Dr . Sugar's research activities are a case i n 
point . Cryptococcus neoformans, a genus of 
yeast-like fungi , can have serious consequen-
ces i n AIDS patients. Sugar and other Section 
researchers have actively been investigating 
cryptococcosis and other fungal infections, 
such as candidiasis, w h i c h are some of the 
most c o m m o n infections to be seen i n AIDS 
patients. 
Even before the outbreak of AIDS i n the 
U.S., the percentage of Amerieans w h o 
developed cryptococcal meningit is had more 
than quadrupled f r o m 1970 to 1980. "There 
were cases of cryptococcosis before AIDS, not 
only as a compl icat ion of treatment w i t h cor-
Drs. Diamond, standing, and Smail, seated, use the Section's 
digital image-processing system to study cellular functions. 
tisone or as a result of certain cancer treat-
ments or i n transplant patients, hut oc-
casionally i n healthy people, and i t wasn't 
clear w h y these people got sick," says Dr . 
Diamond. For that reason, cryptococcosis 
was of particular interest to scientists as a re-
search model . 
N o w , Dr . D i a m o n d adds, cryptococcosis 
represents more than just a model . I t is es-
t imated that the infect ion w i l l develop at 
some point i n 5 to 7 percent of patients w i t h 
AIDS i n the U n i t e d States. There are areas i n 
the U.S. where 15 percent or more of AIDS 
patients have cryptococcal disease, w h i c h 
may develop i n up to 50 percent of the AIDS 
patients i n Africa. I n addit ion, an estimated 
90 percent of AIDS patients suffer f r o m Can-
dida infections, such as thrush and 
esophageal candidiasis. 
Redefining treatment goals 
"We have different goals i n the treatment 
of AIDS patients than those applied to other 
patient groups," explains Dr . Diamond. "Ideal-
ly , what we w o u l d l i k e to do w i t h an infec-
t i o n is to cure i t , hut our experience w i t h 
AIDS is that i t is unusual to do so hecause the 
i m m u n e system is so compromised. Instead, 
our goal has to he to suppress an infect ion, 
and to treat i t as best we can as a chronic i l l -
ness. As i n any other chronic illness, we try 
to provide the patient w i t h as normal a l i fe 
and funct ional capacity as possible." 
Dr . D i a m o n d notes that this goal has been 
di f f i cu l t to achieve: The only pharmaceutical 
treatment for cryptococeosis currently ap-
proved by the F D A is amphoter ic in B, a high-
ly toxic intravenous medicat ion that can 
cause such serious side effects as chil ls , fever. 
Continued on page 6 
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Fungal Infections 
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kidney tox i c i ty and, i n many cases, even 
renal failure. N o w , researchers l ike Dr . Sugar 
are investigating newer drugs that suppress 
the manifestations of cryptococcal disease 
w i t h o u t the t o x i c i t y of the existing treat-
ments. 
Dr . Sugar and Carol Saunders, R .N. , con-
ducted one of the f irst American studies i n 
AIDS patients (the only such study i n N e w 
England) of oral fluconazole, a triazole an-
t i fungal drug manufactured hy Pfizer Inc. 
Pfizer recently f i led a N e w D r u g Appl ica t ion 
for fluconazole for use against systemic can-
didiasis and other fungal infections, and as 
acute maintenance therapy against cryptococ-
cal meningit is (CM). 
Oral fluconazole is related to the i m -
idazole antifungal , ketoconazole, a drug that 
was approved hy the F D A i n the early 1980s 
to treat various fungal diseases, hut was 
found to be ineffective against C M . The drug 
also was found to cause hepatitis i n some 
cases, and i t had negative effects on the en-
docrine system w h e n administered i n h igh 
doses; i n addit ion, the absorption of 
ketoconazole i n the bloodstream is not re l i -
able. 
Dr . Sugar's i n i t i a l study, i n w h i c h enroll-
ment was completed at the end of 1987, was 
an open, non-randomized c l inical t r i a l of oral 
fluconazole as maintenance suppressive 
therapy of disseminated cryptococcosis. 
T w e n t y patients w i t h AIDS, 19 of w h o m had 
cryptococcal meningit is , were studied for up 
to 21 months . A l l of the patients received 
amphoter ic in as pr imary therapy f r o m 20 to 
257 days prior to entry; eight also received 
f lucytosine. Oral fluconazole was ad-
ministered as a single daily dose, at dosages 
ranging f r o m 50 mg. to 200 mg. per day. 
According to Dr . Sugar, oral fluconazole 
generally was well-tolerated hy patients, w i t h 
the most c o m m o n side effects being referable 
to the gastrointestinal tract. There had been 
some reports of l iver tox ic i ty , but a l l such 
cases were reversed when the use of the drug 
was discontinued. Of those patients w h o 
received fluconazole, there was one substan-
tiated relapse, result ing i n a promis ing 5-
percent relapse rate that the researchers say 
merits further study. 
Other studies of fluconazole that Dr . Sugar 
w i l l conduct include a randomized, acute-
treatment study that w i l l compare am-
photer ic in B to oral fluconazole i n patients 
w i t h cryptococcal meningit is w h o have had 
no previous therapy. The Section also is 
receiving patient referrals for a new drug 
called itraconazole, w h i c h also has a broad 
spectrum of antifungal act iv i ty . 
Fluconazole effective against thrush 
W h i l e testing oral fluconazole as a treat-
ment for C M , Dr. Sugar also found the drug to 
he effective against thrush and Candida 
esophagitis. " In many AIDS patients w i t h 
thrush, the infect ion progresses in to the 
esophagus, leading to a vicious cycle—the 
pain makes i t d i f f i cu l t for patients to eat, thus 
contr ibut ing to m a l n u t r i t i o n and, eventually, 
to increased i m m u n e suppression." 
Dr . Sugar w i l l he studying a new drug re-
lated to fluconazole that w i l l be used i n treat-
ing patients w i t h thrush and esophagitis, 
w h i c h may he effective i n treating C M as w e l l . 
Other Section members have actively been 
researching Cryptococcus neoformans and 
Candida albicans, inc luding Edwin Smail, 
M . D . , who is examining the products of Can-
dida and how they interfere w i t h neutrophi l 
effectiveness i n combating infect ion. He also 
is exploring how the organism itself modu-
lates the i m m u n e response. 
Dr . Smail runs the Section's microscopic 
imaging area, w h i c h allows researchers to 
study the biochemical changes of natural ly 
fluorescent probes placed inside a cell i n order 
to f o l l o w cellular functions — for example, 
the neutrophils ' response to Candida. 
Stuart Eevitz, M . D . , is studying how the 
i m m u n e system interacts and k i l l s cryptococ-
ci hy examining the hasic mechanisms of the 
macrophage, and how the act ivation of the 
macrophage can make a cell more readily ahle 
to k i l l the fungus. For instance, he has been 
ahle to define some of the factors that en-
hance the k i l l i n g of cryptococcus, inc luding 
interferon gamma. From this research. Dr. 
Eevitz hopes to be ahle to understand how the 
i m m u n e system breaks down, and how i t can 
he reconstituted. 
Dr . Diamond's research interests involve 
the study of Candida. One recent study 
focused on the feeding of yeast to vascular en-
dothelial cells, w h i c h ingest the yeast but do 
not k i l l i t . He examined the specificity of 
neutrophils i n destroying Candida and the 
damage to the endothelial cells as a result of 
Continued on page 7 
Noteworthy 
Yvonne O'Meara, M.D. , a fe l low i n the Renal 
Section, was awarded the Amer ican Society of 
Nephrology/Nat ional Kidney Founda-
t i o n / M a r i o n Laboratories fe l lowship. Steven 
Balkan, M.D. , of the same Section, was 
awarded a Clinician-Scientist A w a r d f r o m the 
Amer ican Heart Association. David I. Salant, 
M.D. , chief of the Section, recently hecame a 
member of the Pathology A Study Section of 
the N a t i o n a l Institutes of Heal th . 
Neil Rnderman, M.D. , of the Diabetes 
U n i t , w i l l lecture on hyperglycemia and 
atherosclerosis as part of an N I H Consensus 
Panel. The U n i t recently received a t ra ining 
grant f r o m the Amer ican Diabetes Associa-
t i o n . 
Norman Levinsky, M.D. , president of the 
Association of Professors of Medicine, or-
ganized and presided over the annual winter 
meeting of the group. The meeting was held 
i n Tucson, A r i z . Dr . Levinsky also has been 
appointed chairman of the Commit tee on the 
End-Stage Renal Disease Program at the 
Ins t i tute of Medicine. 
Barbara Gilchrest, M.D. , chief of the 
Department of Dermatology, has been ap-
pointed to the Nat iona l Advisory Counc i l on 
Aging at the N I H . Tania Phillips, M.D. , of the 
same Department, recently w o n an American 
Forum Research A w a r d for her w o r k on cul -
tured epidermal allografts i n the treatment of 
s k i n ulcers. 
R. Knight Steele, M.D., chief of the 
Geriatrics Section, was elected to member-
ship i n the American Cl in ica l and 
Climatologieal Association. He also hecame a 
fe l low of the Nat iona l Bureau of Economic 
Research. He recently gave the Beverly Lec-
ture at the annual meeting of the Association 
for Gerontology i n Higher Education. 
David Beller, Ph.D. , chief of the I m m u n o l -
ogy U n i t , was chairman of the workshop on 
"Role of Cytokines i n T-Cel l Ac t iva t ion" at 
the annual EASEB meeting i n N e w Orleans. 
Joseph Stokes, M.D. , of the Preventive 
Medicine/Epidemiology Section, received the 
1989 American College of Preventive 
Medicine Dist inguished Service A w a r d at the 
organization's annual meeting, held i n A p r i l 
i n At lanta , Ga. Dr. Stokes also moderated a 
plenary session on "Control of Hyper-
l ip idemia" at the annual Amer ican Heart As-
sociation meeting. 
Jay Coffman, M.D. , chief of the Peripheral 
Vascular Section and associate director of the 
Evans Department, was elected president-
elect of the new Society for Vascular 
Medic ine and Biology. Richard Cohen, M.D. , 
also of the Section, is secretary-treasurer of 
the Amer ican Federation for Cl in ica l 
Research. 
Ronald McCaffrey, M.D. , chief of the M e d i -
cal Oncology Section, was elected a fe l low of 
the Royal College of Physicians i n Ireland. 
Mark Moskowitz, M.D. , chief of the 
General Medicine Section, is chairman-elect 
of the Eastern seetion of the Amer ican Federa-
t i o n of C l i n i c a l Research. Karen Freund, 
M.D. , of the same Section, is the recipient of 
the Amer ican College of Physicians As-
sociates Cl in ica l Paper A w a r d for her study 
on "Predictors of Smoking Cessation: The 
Framingham Study." Robert Friedman, M.D. , 
also of the Section, received an N I H grant to 
study "Blood Pressure C o n t r o l i n the Elderly: 
Evaluation of a Telephone-l inked Computer." 
Stuart Eevitz, M.D. , of the Infectious Disease 
Section, was the recipient of a grant f r o m 
N I H for his study of "The Role of Macro-
phages i n Cryptococcal Infections." 
David Center, M.D. , of the Pulmonary Sec-
t ion , was promoted to the rank of professor of 
medicine at Boston Univers i ty School of 
Medicine. Jerome S. Brody, M.D. , of the 
same section, was elected to the Association 
of Amer ican Physicians and has become 
editor of the American Journal of Respiratory 
Cell and Molecular Biology. Also i n the Pul-
monary Section, Dennis J. Beer, M.D. , 
received a Career Investigation A w a r d f r o m 
the Amer ican Lung Association. 
Fungal Infections 
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this process. 
"What we are studying i n the Section is a 
dynamic interaction, w h i c h depends on the 
relationship between the organism's abi l i ty to 
adapt and the specific properties of the host. 
"It's a complicated business, because the 
body's response to infect ion is miraculously 
f ine-tuned. We're t r y i n g to get around the 
s i tuat ion i n w h i c h we are robbing Peter to 
pay Paul: We're researching infections i n part 
hecause other scientists have made so m u c h 
progress i n other areas, w h i c h can i n t u r n af-
fect the patient's i m m u n e system — hut i f we 
are ahle to 'rev u p ' the i m m u n e response, w i l l 
we he creating more in f lammatory disease? 
Clearly, that's not what we want ." • 
Suggested further reading 
1. A . M . Sugar, C. Saunders: Oral fluconazole as 
suppressive therapy of disseminated cryptococcosis 
i n patients w i t h acquired i m m u n e deficiency 
syndrome. Am J Med 85: 481-489, 1988. 
2. J. E. Edwards Jr., D . Rotrosen, J. W. Fontaine, C. 
C. Haudenschild, and R. D . D i a m o n d : N e u t r o p h i l -
mediated protect ion of cul tured h u m a n vascular en-
dothel ia l cells f r o m damage hy growing Candida al-
bicans hyphae: Blood 69: 1450-1457, 1987. 
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E vans/Transition 
John Wilson, M.D. , has heen named chief resi-
dent for the 1989-1990 academic year. Born 
i n M i l w a u k e e , Wis. , and raised i n 
Pittsburgh, Pa., Dr . Wi l son received his medi -
cal degree f r o m Pennsylvania State Univers i ty 
College of Medic ine at Hershey. He is f in ish-
ing his t h i r d year as a resident i n internal 
medicine and w i l l start his chief residency 
J u l y l . 
Fo l lowing his year as chief medical resi-
dent. Dr . W i l s o n expects to hegin a cardiology 
fe l lowship, a l though he is not sure where at 
this t ime . " I 'd l i k e to be w o r k i n g somewhere 
on the East Coast, preferably i n Boston," he 
notes. 
I n addi t ion to administrat ive and patient-
care duties, Dr . W i l s o n w i l l he involved i n i n -
s truct ing second-year medical students. 
Regarding his long-term goals i n medicine. 
Dr . W i l s o n notes that " I ' m interested i n doing 
invasive cardiology at an academic i n s t i t u -
t i o n . Academic medicine w i l l def initely play 
some role i n m y future." 
Thir teen Evans members w i l l complete 
their residencies i n July. The graduates and 
their future pursuits, i f k n o w n , are: 
David Cohen, M.D. , Brigham and Women's 
Hospital (nephrology) 
Moira Cunningham, M . D . ( internal medicine) 
Mary Delaney, M.D. , The Univers i ty Hospita l 
(endocrinology) 
Dale Janik, M . D . (gastroenterology) 
Bing K G , M . D . ( internal medicine) 
Jeffrey Leavitt, M.D. , Boston Univers i ty 
Medical Center (cardiology research 
fellowship) 
Michael Lev, M . D . (neuroradiology) 
Scott Machler, M.D. , Univers i ty of 
Pennsylvania (neuropharmacology) 
Harry Shapiro, M.D. , Veterans Adminis t ra -
t i o n Hospital , Bedford (internal medicine) 
Alice Sheridan, M.D. , The Univers i ty 
Hospital (nephrology) 
DuWayne Willett, M . D . (mi l i tary service) 
John Wilson, M.D. , The Univers i ty Hospita l 
(chief resident, medicine) 
Richard Vogel, M.D. , The Univers i ty 
Hospital (cardiology) 
A message from tfie editor 
Please take a moment to complete the 
postage-paid response card that is enclosed 
in this issue, indicating areas of interest that 
you would like to see covered in future issues 
of Evans Medicine. Thank you. 
New chief medical resident 
John Wilson, M . D . 
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